N-[(1R,2R)-2-Aminocyclohexyl]-N'-[3,5-bis(trifluoromethyl)phenyl]thiourea, 97%, 50mg

(2E)-3-(3-FORMYL-4-HYDROXYPHENYL)PROP-2-ENOIC ACID, 95%, 10g

2-(4-Bromophenyl)-2-oxoacetic acid, 95.0%, 5g

tert-Butyl 2-(3-aminophenoxy)acetate, 98%, 5g

2-CHLORO-4-HYDROXYBENZOIC ACID HYDRATE, 97.0%, 1g

2-Bromo-N-(piperidine-4-yl)benzamido hydrochloride, 95.0%, 1g

(3-Aminopyrazol-4-yl)(2-thienyl)methanone, 95.0%, 1g

Éster isopropílico del ácido mirístico, mínimo 92 %, extrapuro, 2,5 l, envase de vidrio

4-Chloro-1H-pyrrolo[2,3-b]pyridine-2-carboxylic acid, 95.0%, 500mg

2-Amino-6-methoxypyrimidin-4(3H)-one, 97%, 1g

tert-Butyl 4-(pyrrolidin-3-yl)piperazine-1-carboxylate hydrochloride, 97%, 5g

3,4-Dichloro-n-methylbenzenesulfonamide, 97%, 5g

3-(2-methoxyethyl)-5-methylimidazolidine-2,4-dione, 95.0%, 250mg